Susceptibility testing was performed on Dientamoebafragilis ATCC 30948 in a dixenic culture with Kkebsiella pneumoniae and Bacteroides vulgatus. D. fragilis was cocultured with the bacteria in TYGM-9 medium (ATCC medium 1171). The activities of antiparasitic drugs were assessed by counting viable D. fragilis trophozoites with a hemacytometer by trypan blue exclusion. The minimal amebicidal concentrations of the following four drugs were determined: iodoquinol at 128 ,ug/ml, paromomycin at 16 ,ug/ml, tetracycline (questionably) at 32 ,ug/ml, and metronidazole at 32 ,ug/ml.
Dientamoeba fragilis is a protozoan parasite described and named by Jepps and Dobell in 1918 (9) . It resides in the human large intestine. The organism is now classified as a flagellate (12) , but it has no demonstrable flagella or a cyst stage. The distribution of this organism is worldwide, with reported incidences of 1.4 to 53% (3, 4, 11, 14, 17, 19, 22) .
Although often considered harmless, D. fragilis has been associated with a variety of symptoms. Abdominal pain, diarrhea, abnormal stools, loss of appetite, and weight loss are the common symptoms that have been described previously (22) . Wenrich et al. (21) reported that there is a higher incidence of gastrointestinal disorders among college students harboring D. fragilis than among those infected with Entamoeba histolytica. Sapero (15) found that 27.3% of the patients infected with D. fragilis had symptoms, and Steinitz et al. (18) reported symptoms in 15.1% of infected individuals. In Canada, an incidence of 25% symptomatic cases was reported by Yang and Scholten (22) . However, the pathogenicity of D. fragilis has been questioned, mainly because studies of its prevalence and associated symptoms were uncontrolled and they suffered from selection bias. Randomized, double-blind controlled studies are needed to determine the pathogenic roles of this parasite.
In a retrospective study of "pure" D. fragilis infections, Spencer et al. (17) found gastrointestinal symptoms in 32 (91%) of 35 children. It was noted that diarrhea was the most common finding in patients with acute illness, whereas abdominal pain was more common in children with chronic symptoms. Treatment with iodoquinol or metronidazole was effective. Similar findings were also reported by the same group of investigators (16) 16 jig/ml, tetracycline at 32 jig/ml, and metronidazole at 32 jig/ml (Table 1) . Because these antiparasitic drugs could also be antibacterial, we performed agar dilution testing on K pneumoniae and B.
vulgatus, the two supporting bacteria in the D. fiagilis culture.
Serial doubling dilutions of the four drugs were prepared in Mueller-Hinton agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) with 5% defibrinated sheep blood. On the basis of the amebicidal results obtained with D. fragilis, the following ranges of serial doubling dilutions of the four drugs were prepared in the agar dilution test: 128 to 1 jig/ml for iodoquinol, 16 to 1 jig/ml for paromomycin, 32 to 1 jig/ml for tetracycline, and 32 to 1 jig/ml for metronidazole.
While the K pneumoniae strain in the dixenic culture appeared to be uniform in colonial morphology, B. vulgatus presented consistently with two different colony sizes which we designated Bi (small colonies) and B2 (large colonies). The biochemical reactions of variants Bi and B2 were similar (data not shown). We include here susceptibility studies on both the Bi and B2 variants of B. vulgatus.
Fresh (24-h) cultures of K pneumoniae as well as the B1 and B2 variants of B. vulgatus were suspended in 5 ml of MuellerHinton broth (Oxoid Limited, Basingstoke, England) to match a 0.5 McFarland turbidity standard (approximately 108 CFU/ ml). These bacterial suspensions were further diluted 1 in 10 to give a concentration of 107 CFU/ml. A 1-jil volume of this diluted suspension was inoculated onto each plate of the drug dilution series. A control plate with no drugs was included as a growth control. All the inoculated plates were incubated anaerobically at 35°C for 48 h.
The MICs of the four drugs for the bacteria are given in Table 2 . There was no inhibition of K pneumoniae or B. vulgatus (both Bi and B2 variants) by iodoquinol (highest concentration tested, 128 jig/ml) or paromomycin (highest concentration tested, 16 jig/ml). The K pneumoniae strain was highly susceptible to tetracycline, (MIC, <1 jig/ml). There was a twofold difference in the tetracycline MICs for the two B. vulgatus variants: 16 jig/ml for variant Bi and 32 ,ug/ml for variant B2. Metronidazole up to a concentration of 32 ,ug/ml did not exhibit any inhibitory activity against K pneumoniae, while both B. vulgatus variants were inhibited by metronidazole at a concentration of -1 jg/ml.
By comparing the activities of the four drugs against D. fragilis in the dixenic culture and the bacterial isolates, we were led to the following conclusions. Because of the lack of antibacterial activity by iodoquinol and paromomycin under the test conditions of the present study, the amebicidal activity exerted against D. fragilis should be directly related to these two drugs. On the other hand, the activity of tetracycline against D. fragilis was difficult to assess. The K pneumoniae strain was highly susceptible to tetracycline (-1 jig/ml), and both variants of B. vulgatus were inhibited by tetracycline at a concentration of 32 jig/ml, the same concentration at which depletion of live D. fragilis trophozoites was observed. The inhibition of growth of D. fragilis by tetracycline might be attributed to this concentration of the drug or it may be a result of the depletion of the bacteria which supported the growth of the trophozoites. Metronidazole was highly active against both B. vulgatus variants (MIC, <1 jig/ml), but it had no activity against K pneumoniae. This can be expected because the cytotoxic selectivity of metronidazole results from the necessity of the drug to be reduced to an active cytotoxic form, and this does not occur in aerobic cells (10 (17) as an effective agent. However, the drug's mutagenicity and carcinogenic potential make it a less than ideal drug for use in children (20) . As with the other three drugs tested, experimental details on the susceptibility testing of metronidazole against D. fragilis are also lacking.
We demonstrated in the present study that, in the absence of an axenic culture, an in vitro drug susceptibility test can be performed on D. fragilis in the presence of growth-supporting bacteria. The minimal amebicidal concentrations on D. fragilis determined in our study were 128 ,ug/ml for iodoquinol, 16 ,ug/ml for paromomycin, 32 ,ug/ml (questionably) for tetracycline, and 32 ,ug/ml for metronidazole. It 
